Promoting Recovery After STroke With Amantadine
University of Pennsylvania
Summary
The investigators aim to examine whether amantadine can help patients recover from stroke. This will be a blinded randomized clinical trial (RCT). Patients will be randomized post-ischemic or hemorrhagic stroke either to the placebo arm or amantadine arm. Patients will be on study drug or placebo for 1 month but will be enrolled for 3 months total. At various time points patients will be examined and fill out questionnaires to determine level of stroke recovery.
Eligibility
- Age range
- 18–85 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: 1. 18 to 85 years old, male and female 2. Modified Rankin Score (mRS)\<=2 prior to stroke 3. Ischemic or hemorrhagic stroke as diagnosed by vascular neurologist or as proven on magnetic resonance imaging (MRI) or non-contrast head computed tomography NCHCT) 4. 24 hours to 3 weeks after stroke onset or time last known well prior to detection of symptoms 5. National Institute of Health Stroke Scale (NIHSS)\>=3 and NIHSS\<=15 6. Creatinine Clearance of greater than or equal to 60 mL/min using the Cockroft- Gault equation. 7. Have passed a swallow evaluation prior to drug admi…
Interventions
- DrugAmantadine
Amantadine is a antiviral drug and dopamine promoter that is currently approved by the FDA for the treatment of influenza A and Parkinson's Disease
- DrugPlacebo
placebo pills
Location
- The Hospital of the University of PennsylvaniaPhiladelphia, Pennsylvania